IMU 5.56% 5.7¢ imugene limited

Media Thread, page-12623

  1. 2,867 Posts.
    lightbulb Created with Sketch. 11920
    Hi there

    A good question. My answer is: Well - no, I don't think they are deciding dose escalation based on scans of tumour size. The scans are only every 6 weeks or so, and direct effects on tumour size take longer than that - at least to begin with - due to pseudo progression. The CR in Bile Duct cancer appeared to get worse in initial scans - judged by tumour size. I think it was scan 3 before tumour size reduced.

    They have made it pretty clear in their most recent conference presentation that they are measuring a range of immunological data - something like 20 or more immune cell indicators - and that they can demonstrate a correlation between those immunological changes, and tumour response. ie. "Immunological changes in responders are characterized by higher frequencies of T cells, natural killer cells, and monocyte subsets post-treatment."
    Source: https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/65a9aff332d3180e08db85c7/1705619461250/749+ASCO-GI+MAST-Final+%281%29.pdf

    So I assume that they are measuring the immune cell indicators - and using them as a proxy for likely tumour response and efficacy of the treatment, which would take much longer to develop.

    Cheers

    Dave

    Last edited by davybabyk: 23/03/24
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.7¢
Change
0.003(5.56%)
Mkt cap ! $417.2M
Open High Low Value Volume
5.5¢ 5.8¢ 5.2¢ $2.499M 45.00M

Buyers (Bids)

No. Vol. Price($)
2 1921794 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.7¢ 1368288 7
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.